Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2003



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Basic Aspects of Tumor Immunology (C5)


Organizer(s) Nicholas P. Restifo and Nina Bhardwaj
February 17—23, 2003
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Oct 17, 2002
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Dec 17, 2002

Sponsored in part by The Director's Sponsor Fund

Summary of Meeting:
The past decade has seen great strides in the field of tumor immunology. High avidity CD8+ and CD4+ T cells from the available human T cell repertoire have been used to identify a large number of tumor-associated antigens. We have devised immunization strategies that enable us to boost immune responses against these antigens and some encouraging, but preliminary, results have been obtained in the clinic. Despite much excitement, these advances have not yet led to reproducibly effective cancer treatments. The challenge now is to gain a deeper understanding of how immune cells interact with and potentially destroy tumor cells. This meeting will bring together experts from academia and industry in an effort to elucidate the basic immunology that could make it possible to trigger and sustain an immune response capable of mediating the complete destruction of tumor cells.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


MONDAY, FEBRUARY 17

15:00—19:00
Registration

Shavano Peak Foyer
18:15—19:15
Welcome

Shavano Peak Foyer
19:15—19:30
Orientation

Crestone/Red Cloud
19:30—20:30
Opening Remarks
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
Philippa C. Marrack, HHMI/National Jewish Health, USA
What a Tumor Specific T Cell Response Might Look Like


TUESDAY, FEBRUARY 18

07:00—08:00
Breakfast

Shavano/Torreys
08:00—09:00
Keynote Address: Adoptive Cell Transfer
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Nicholas P. Restifo, NCI, National Institutes of Health, USA
What Animal Models Teach about Adoptive Transfer of "Self-" Specific, Anti-Tumor T Cells

09:00—09:20
Coffee Break

Shavano Peak Foyer
09:20—11:00
Novel Cellular Immunotherapies: Adoptive Transfer
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Nicholas P. Restifo, NCI, National Institutes of Health, USA

Philip D. Greenberg, University of Washington, USA
Attack of the Killer Clones: Immunotherapies Based on the Adoptive Transfer of Tumor-Reactive CD8+ T Cells

Stephen P. Schoenberger, La Jolla Institute for Allergy and Immunology, USA
Short Talk: T Help for CTL Secondary Expansion

11:00—13:00
Poster Setup

Torreys Peak
13:00—22:00
Poster Viewing

Torreys Peak
15:00—16:30
Workshop 1: New Mouse Models / Novel Recombinant and Synthetic Vaccines

Crestone/Red Cloud
Ross M. Kedl, University of Colorado Denver, USA
Immunization with an Altered TRP2 Peptide Ligand in Conjunction with TLR7 Specific Stimulation Elicits Strong CTL Responses against Melanoma

W. Martin Kast, University of Southern California, USA
Establishment of an HLA-A*0201 Human Papilloma-Virus Type 16 Tumor Model to Determine the Efficacy of Vaccination Strategies in HLA-A*0201 Transgenic Mice

Federica Cavallo, University of Turin, Italy
DNA Electroporation Halts in situ Carcinoma in HER-2/neu Transgenic Mice

Yang Liu, University of Michigan, Ann Arbor, USA
Analysis of Tumor-Reactive T Cells Using P1A-Specific Transgenic Mice: Repertoire, Effector Function, and Tumor Evasion

Matthew F. Mescher, University of Minnesota, USA
Large Mutivalent Immunogen (LMI) for Tumor Immunotherapy: Basic and Clinical Studies

16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Identification of Target Antigens
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
Victor H. Engelhard, University of Virginia, USA
Recognition of Melanocyte Differentiation Antigens: Self-Tolerance, Autoimmunity, and Cancer Immunotherapy

Pierre G. Coulie, University of Louvain, Brussels, Belgium
Immunological Analysis of Patients Vaccinated with MAGE Antigens

Ken-ichi Hanada, National Cancer Institute, National Institutes of Health, USA
Short Talk: A Novel Protein Splicing Mechanism Generates an HLA-A3 Restricted Epitope from the Tumor-Associated Antigen FGF-5

* Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Tumor Antigens Recognized by CD4+ T Cells

19:00—20:00
Social Hour

Torreys Peak
20:00—22:00
Poster Session 1: Targeting Tumor Associated Antigens in Mouse and Man

Torreys Peak

WEDNESDAY, FEBRUARY 19

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:00
Novel Immunotherapies: Active Immunization
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
Steven A. Rosenberg, NCI, National Institutes of Health, USA
The Immune Response to Human Cancer

Hans Schreiber, University of Chicago, USA
Unique Tumor Antigens: New Lessons for Cancer Immunity

Pedro Romero, University of Lausanne, Switzerland
Targeting Tumor-Specific Antigens Using Natural and Modified Peptides

Alessandro Sette, La Jolla Institute for Allergy & Immunology, USA
Epitope Modification and Vaccine Design for Cancer Immunotherapy

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:00—13:00
Poster Setup

Torreys Peak
13:00—22:00
Poster Viewing

Torreys Peak
15:00—15:35
Special Lecture

Crestone/Red Cloud
Shimon Sakaguchi, Osaka University, Japan
Naturally Arising CD25+CD4+ Regulatory T Cells in Autoimmunity and Tumor Immunity

15:35—16:30
Workshop 2: Adoptive Cell Transfer/Dendritic Cell Vaccines/ Whole Cell Vaccines

Crestone/Red Cloud
Willem W. Overwijk, Nektar Therapeutics, USA
In vivo Requirements for Destruction of Large Established Tumors by Self-Specific CD8+T Cells

Ephraim J. Fuchs, Johns Hopkins School of Medicine, USA
Tumor Vaccines after Allogeneic Bone Marrow Transplantation

Suzanne Ostrand-Rosenberg, University of Maryland, USA
Stat6 Gene Inhibits Constitutive Immunity to Metastatic Cancer

Brian J. Czerniecki, University of Pennsylvania, USA
Defining DC Requirements for Activating High Functional Avidity Anti-Tumor CD8+ T Cells

16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Autoimmunity and the Immunotherapy of Cancer
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Pamela S. Ohashi, Princess Margaret Cancer Centre, Canada
Understanding T Cell Decisions between Tolerance and Activation

Joan Goverman, University of Washington, USA
Regulation of CD8+ T Cells In Vivo: Tolerance Versus Autoimmunity in Myelin Basic Protein-Specific Cytotoxic T Cells

Elizabeth M. Jaffee, Johns Hopkins University, USA
Reversal of CD8+ Peripheral Tolerance in the HER-2/neu Transgenic Mice by Deletion of CD4+CD25+ Regulatory T Cells

19:00—20:00
Social Hour

Torreys Peak
20:00—22:00
Poster Session 2: Lessons: The Study of Autoimmunity and Transplantation

Torreys Peak

THURSDAY, FEBRUARY 20

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:00
Impediments to Vaccine Function
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Jonathan W. Yewdell, NIAID, National Institutes of Health, USA
Overcoming Immunodominance in CD8+ T Cell Responses

Yutaka Tagaya, Institute of Human Virology, USA
Short Talk: A Novel IL15Ralpha-Mediated Therapeutic Strategy Against Cancer

Thomas Spies, Fred Hutchinson Cancer Research Center, USA
Significance of NKG2D Receptor and its Tumor-Associated Ligands

Robert D. Schreiber, Washington University School of Medicine, USA
Cancer Immunoediting: From Immunosurveillance to Tumor Escape

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:00—13:00
Poster Setup

Torreys Peak
13:00—22:00
Poster Viewing

Torreys Peak
15:00—16:30
Workshop 3: Negative Regulatory Molecules / Suppressor Cells / Tumor Escape

Crestone/Red Cloud
Thomas Gajewski, University of Chicago, USA
Overcoming Negative Regulation of Anti-Tumor T Cell Responses

Vincenzo Bronte, University of Verona, Italy
Immune Dysfunction Induced by Myeloid Suppressor Cells in Tumor-Bearing Mice

Jay A. Berzofsky, NCI, NIH, USA
Negative Regulation of Tumor Immunosurveillance

Barbara Seliger, Martin Luther University, Germany
Multiple Mechanisms Causing Deficient Expression and Function of MHC Class I Antigen Processing Components in Tumors

16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Antigen Presenting Cells in the Anti-Tumor Immune Response
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
Mark M. Davis, Stanford University School of Medicine, USA
Requirements for T Cell Activation and the Role of CD4

* Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Antigen Presenting Cells in the Regulation of Natural and Therapeutic Antitumor Immune Responses

Rienk Offringa, Genentech Inc., USA
Role of Serine Protease Inhibitors (Serpins) in Dendritic Cell Survival and Tumor Immune Escape

19:00—20:00
Social Hour

Torreys Peak
20:00—22:00
Poster Session 3: Impediments to the Anti-tumor Immune Response

Torreys Peak

FRIDAY, FEBRUARY 21

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:00
Tracking the Anti-Tumor Immune Response
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Precision Guiding of Cytolytic T-Lymphocyte Responses

Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Regulation of T Cell Immunity by Dendritic Cells

Vincenzo Cerundolo, University of Oxford, UK
Vaccination Strategies Using Poly-Epitope Constructs

Steven J. Burakoff, New York University School of Medicine, USA
Negative Regulators of TCR Signaling: Potential Mechanisms of T Cell Tolerance

Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Costimulatory Requirements of Genetically Targeted T Cells

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:00—13:00
Poster Setup

Torreys Peak
13:00—22:00
Poster Viewing

Torreys Peak
15:00—15:35
Special Lecture

Crestone/Red Cloud
Ronald Levy, Stanford University, USA
Vaccination Against the Antigen Receptor (Idiotype) for the Therapy of Lymphoma

15:35—16:30
Workshop 4: Ongoing Preclinical and Clinical Efforts I

Crestone/Red Cloud
Maria Pia Protti, H San Raffaele, Italy
Defining the Helper Epitope Repertoire on Tumor Antigens to Study CD4+ T Cells in Neoplastic Patients

Patrick Hwu, University of Texas MD Anderson Cancer Center, USA
Intralymphatic Dendritic Cell Immunization of Patients Induces Tumor-Specific Skin Homing T Cells

Jan Alvar Lindencrona, Karolinska Institute, Sweden
Tumor Vaccination Based on the Her2/neu Oncogene; Lessons Learned from Murine Models

16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Negative Regulatory Influences on Anti-Tumor T Cell Function
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Removing the Brakes: Enhancement of Antitumor Responses by CTLA-4 Blockade

* Hyam I. Levitsky, , USA
Tumor-Specific T Cell Anergy and the Immunosurveillance Hypothesis: Reactivating the Seeds of the Cure

Linda A. Sherman, The Scripps Research Institute, USA
Tolerance vs. Immunity for Naive and Memory CD8 T Lymphocytes

19:00—20:00
Social Hour

Torreys Peak
20:00—22:00
Poster Session 4: The Conduct and Assessment of Clinical Trials

Torreys Peak
20:00—21:30
An Editors' Roundtable
Goals: - To demystify the process of Editorial Review by briefly explaining how each journal works. - To address questions regarding editorial bias / subjectivity. Can bias help a journal by giving it direction and focus? Can it hurt? - How do Editors judge reader interest levels? Do Editors independently evaluate quality of scientific data? Do they attempt to evaluate the truthfulness of papers? - How do Editors make themselves aware conflicts of interest in authors and reviewers?

Crestone/Red Cloud
Alison Farrell, Nature Publishing Group, USA

Stephen James Simpson, Arthritis Research UK, UK

Jennifer Buckland, Nature Reviews Immunology, UK


SATURDAY, FEBRUARY 22

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:00
Death and the Immune Response
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Vishva M. Dixit, Genentech, Inc., USA
New Players in an Old Field - Novel TNF Family Members

Harriet L. Robinson, GeoVax Inc., USA
New DNA vaccine approaches involving the induction of apoptosis

Michael J. Lenardo, NIAID, National Institutes of Health, USA
Human Genetic Analysis of Apoptosis in Lymphocytes

Nina Bhardwaj, Icahn School of Medicine at Mt Sinai, USA
Modulation of Immunity by Dendritic Cells

09:20—09:40
Coffee Break

Shavano Peak Foyer
14:00—15:15
Workshop 5: Ongoing Preclinical and Clinical Efforts II

Crestone/Red Cloud
Craig L. Slingluff, University of Virginia, USA
Multi-Epitope Peptide Vaccines for Melanoma: Sytemic and Local Adjuvants

Francine Jotereau, Institut de Biologie, France
Thereapeutic Efficacy and Antigen Specificity of Melanoma Reactive TIL Infused to Melanoma Stage III Patients

Robert G. Urban, Johnson & Johnson Innovation, USA
The Use of Bio Compatible Polymers to Deliver Plasmid DNA Immunogens

John G. Gribben, Dana Farber Cancer Institute, USA
A Phase I DNA Immunization Trail Targeting the Tumor Associated Antigen Cyp1B1

15:15—16:30
Workshop 6: Ongoing Preclinical and Clinical Efforts III

Crestone/Red Cloud
Bernard A. Fox, Earle A Chiles Research Institute, USA
Vaccination of Reconstituted Lymphopenic Hosts: Translating an Effective Preclinical Strategy into Clinical Trials

Thomas W. Dubensky, Jr., Tempest Therapeutics, USA
Effective Priming of CD8+ T-Cells with Vaccines Derived from Selected Strains of Listeria Monocytogenes

Manley T. Huang, Genencor International, USA
Development of Therapeutic DNA Vaccines for Oncogenic Viruses

Jonathan J. Lewis, Antigenics, USA
Translational Biology of Heat Shock Protein (HSP) Vaccines in Cancer

16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Vaccines Based on Tumor Cells or Tumor Cell Extracts
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Nina Bhardwaj, Icahn School of Medicine at Mt Sinai, USA

Arthur M. Krieg, Checkmate Pharmaceuticals, USA
Anti-Tumor Mechanisms of Oligodeoxynucleotides with CpG and Poly-G Motifs

Eli Gilboa, University of Miami, Miller School of Medicine, USA
Immunotherapy of Cancer with Tumor RNA Transfected Dendritic Cells

Jacques F. Banchereau, The Jackson Laboratory for Genomic Medicine, USA
Dendritic Cells as Melanoma Vaccines

19:00—20:00
Social Hour

Shavano/Torreys
20:00—23:00
Entertainment

Shavano/Torreys

SUNDAY, FEBRUARY 23

 
Departure


*Session Chair †Invited, not yet responded.



We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676